Specific determination of hepatitis B e antigen by antibodies targeting precore unique epitope facilitates clinical diagnosis and drug evaluation against hepatitis B virus infection.

Specific determination of hepatitis B e antigen by antibodies targeting precore unique epitope facilitates clinical diagnosis and drug evaluation against hepatitis B virus infection.
复制标题

通过针对 precore 独特表位的抗体特异性测定乙型肝炎 e 抗原,有助于针对乙型肝炎病毒感染的临床诊断和药物评价

DOI:
10.1080/22221751.2020.1862631
复制
发表时间:
2021-12
影响因子:
13.2
通讯作者:
Xia NS
Xia NS
中科院分区:
医学2区
文献类型:
--
作者:
Wang SJ;Chen ZM;Wei M;Liu JQ;Li ZL;Shi TS;Nian S;Fu R;Wu YT;Zhang YL;Wang YB;Zhang TY;Zhang J;Xiong JH;Tong SP;Ge SX;Yuan Q;Xia NS

文献摘要

参考文献

被引文献

相似文献

Hepatitis B e antigen (HBeAg) is a widely used marker both for chronic hepatitis B (CHB) clinical management and HBV-related basic research. However, due to its high amino acid sequence homology to hepatitis B core antigen (HBcAg), most of available anti-HBe antibodies are cross-reactive with HBcAg resulting in high interference against accurate measurement of the status and level of HBeAg. In the study, we generated several monoclonal antibodies (mAbs) targeting various epitopes on HBeAg and HBcAg. Among these mAbs, a novel mAb 16D9, which recognizes the SKLCLG (aa −10 to −5) motif on the N-terminal residues of HBeAg that is absent on HBcAg, exhibited excellent detection sensitivity and specificity in pairing with another 14A7 mAb targeting the HBeAg C-terminus (STLPETTVVRRRGR, aa141 to 154). Based on these two mAbs, we developed a novel chemiluminescent HBeAg immunoassay (NTR-HBeAg) which could detect HBeAg derived from various HBV genotypes. In contrast to widely used commercial assays, the NTR-HBeAg completely eliminated the cross-reactivity with secreted HBcAg from precore mutant (G1896A) virus in either cell culture or patient sera. The improved specificity of the NTR-HBeAg assay enables its applicability in cccDNA-targeting drug screening in cell culture systems and also provides an accurate tool for clinical HBeAg detection.
DOI: 10.1016/j.antiviral.2016.05.005
发表时间: 2016-08
期刊: ANTIVIRAL RESEARCH
影响因子: 7.6
作者:
Cai, Dawei;Wang, Xiaohe;Yan, Ran;Mao, Richeng;Liu, Yuanjie;Ji, Changhua;Cuconati, Andrea;Guo, Haitao
通讯作者: Guo, Haitao
DOI: 10.1128/jvi.00798-18
发表时间: 2018-12-15
影响因子: 5.4
作者:
Bai L;Zhang X;Kozlowski M;Li W;Wu M;Liu J;Chen L;Zhang J;Huang Y;Yuan Z
通讯作者: Yuan Z
DOI: 10.1073/pnas.83.6.1578
发表时间: 1986-03-01
影响因子: 11.1
作者:
OU, JH;LAUB, O;RUTTER, WJ
通讯作者: RUTTER, WJ
DOI: 10.1128/aac.41.8.1715
发表时间: 1997-08-01
影响因子: 4.9
作者:
Ladner, SK;Otto, MJ;King, RW
通讯作者: King, RW
DOI: 10.1006/viro.1996.0655
发表时间: 1996-12-15
期刊: VIROLOGY
影响因子: 3.7
作者:
Moriyama, K;Okamoto, H;Mayumi, M
通讯作者: Mayumi, M